Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Br J Haematol. 2022 May;197(4):e49-e52. doi: 10.1111/bjh.18044. Epub 2022 Feb 6.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepcidins
  • Humans
  • Nitriles
  • Primary Myelofibrosis* / drug therapy
  • Pyrazoles / therapeutic use
  • Pyrimidines

Substances

  • Hepcidins
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib